These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency.
    Author: Nissen C.
    Journal: Eur J Cancer; 1994; 30A Suppl 3():S12-4. PubMed ID: 7535065.
    Abstract:
    The production of recombinant human granulocyte colony stimulating factor (HuG-CSF) by gene cloning has made this growth factor available in large quantities for clinical application. There is accumulating evidence to suggest that the glycosylation of HuG-CSF confers advantages in terms of in vitro stability to temperature, pH and degradation by proteases, and a recent report attributes a greater biological potency, in the absence of larger biological mass, to the property of glycosylation. In this study, the biological potency of glycosylated rHuG-CSF (lenograstim) was compared with that of non-glycosylated rmetHuG-CSF (filgrastim) and a non-glycosylated rHuG-CSF (non-commercial preparation), using duplicate assays of neutrophil and erythroid colony formation in three human bone marrows. Serial doubling dilutions of each rHuG-CSF resulted in a concentration range of 0.008-128 ng/ml. Qualitative (number) and quantitative (size) assessments of colonies were performed at day 14 of culture. Lenograstim proved twice as potent as filgrastim (and non-commercial rHuG-CSF) at maximal colony stimulation, and 20 times more potent than both at half-maximal colony stimulation (P = 0.0001). Incubation with lenograstim also produced a higher proportion of colonies with > 200 cells than either of the other preparations. In conclusion, glycosylated rHuG-CSF (lenograstim) had a greater qualitative and quantitative potency than the non-glycosylated rHuG-CSFs (filgrastim and non-commercial rHuG-CSF), indicating that glycosylation confers a potency advantage on lenograstim.
    [Abstract] [Full Text] [Related] [New Search]